Company intelligence / Profile preview
MEDIPOST
Seongnam-si, Gyeonggi-do, South Koreaen.medi-post.co.kr ↗
- Ownership
- Public · 078160
- Development stage
- Other
01
Overview
MEDIPOST commercialized the world’s first regulatory-approved allogeneic human umbilical cord blood-derived mesenchymal stem cell product (CARTISTEM®) for knee osteoarthritis. Other programs are advancing through early clinical trials or preclinical development. The company has received over 33 public R&D grants and holds numerous patents related to its technologies
- Therapeutic areas
- PulmonologyNephrologyImmunologyRheumatology
- Modalities
- Umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs)allogeneic cell therapy
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
Technology transfer agreement with LG Chemical for MLSC technology; other partnerships not detailed
04
Financials
- Market cap
- $244.8M
- Total revenue
- $54.4M
- Enterprise value
- $220.2M
Beyond the preview
Go deeper on MEDIPOST.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEDIPOST.